Synthesis and cytotoxicity of bis-1,3,4-oxadiazoles and bis-pyrazoles derived from 1,4-bis[5-thio-4-substituted-1,2,4-triazol-3-yl]-butane and their DNA binding studies

Archiv der Pharmazie

Volumn 344, Issue 4, 2011, Pages 248-254

  Purohit, Madhusudan ^a   Rajendra Prasad, V V S ^d   Mayur, Yergeri C ^b,c  

^a JSS COLLEGE OF PHARMACY   (India)

^b VL College of Pharmacy   (India)

^c Shri Vithal Education and Research Institute s   (India)

^d Sita Messtechnik GmbH   (Germany)

Author keywords

Bis 1,2,4 triazole; Bis 1,3,4 oxadiazole; Bis pyrazole; Cytotoxic activity; MTT assay

Indexed keywords

1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (3 TOLYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (4 ETHOXYPHENYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (4 TOLYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (BUTYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (CYCLOHEXYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (1 OXO 1 (3,5 DIMETHYL PYRAZOL 1 YL) METHYL) THIO 4 (PHENYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (3 TOLYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (4 ETHOXYPHENYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (4 TOLYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (BUTYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (CYCLOHEXYL) 1,2,4 TRIAZOL 3 YL] BUTANE; 1,4 BIS[5 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL METHYL) THIO 4 (PHENYL) 1,2,4 TRIAZOL 3 YL] BUTANE; ANTINEOPLASTIC AGENT; BIS 1,3,4 OXADIAZOLE DERIVATIVE; BIS PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; COLON CARCINOMA; CYTOTOXICITY; DRUG DNA BINDING; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIPOPHILICITY; LUNG CARCINOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, THIN LAYER; DNA; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; MOLECULAR STRUCTURE; OXADIAZOLES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRIAZOLES;

EID: 79953801396     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201000177     Document Type: Article

References (25)

1. P. Yong, Q. Yang, X. Quin, Tetrahedron 2005, 61, 11895-11901.
2. th, Ed, Vol 5, Wiley, Hoboken, NJ 2003, pp. 74-75.
3. B. S. Holla, R. Gonsalves, S. Shenoy, ILFarmaco 1998, 53, 574-578.
4. J. Coro, R. Perez, H. Rodriguez, M. Suarez, C. Vega, M. Rolon, D. Montero, J. J. Nogalc, A. Gomez-Barrioc, Bioorg. Med. Chem. 2005, 13, 3413-3421.
5. S. M. Sondhi, S. Jain, M. Dinodia, R. Shukla, R. Raghubir, Bioorg. Med. Chem. 2007, 15, 3334-3344.
6. E. Pomarnacka, A. Kornicka, Il Farmaco 2001, 56, 571-577.
7. I. Antonini, S. Santoni, R. Lucciarini, C. Amantini, D. D. Ben, R. Volpini, G. Cristalli, J. Med. Chem. 2008, 51, 997-1006.
8. M. F. Brana, J. M. Castellano, D. Perron, C. Maher, et al., J. Med. Chem. 1997, 40, 449-454.
9. G. W. Rewcastle, W. A. Denny, B. C. Baguley, J. Med. Chem. 1987, 30, 843-851.
10. S. A. Gamage, J. A. Spicer, G. J. Atwell, G. J. Finlay, et al., J. Med. Chem. 1999, 42, 2383-2393.
11. J. A. Spicer, S. A. Gamage, G. W. Rewcastle, G. J. Finley, et al., J. Med. Chem. 2000, 43, 1350-1358.
12. V. V. Dabholkar, F. Y. Ansari, Acta Pol. Pharm. Drug Res. 2008, 65 (5), 521-526.
13. B. S. Holla, R. Gonsalves, S. Shenoy, Eur. J. Med. Chem. 2000, 35, 267-271.
14. B. S. Holla, K. N. Poojary, B. S. Rao, M. K. Shivananda, Eur. J. Med. Chem. 2002, 37, 511-517.
15. M. M. Ghorab, A. M. Sh. El-Sharief, Y. Ammer, Sh. I. Mohammed, Il Farmaco 2000, 55, 354-361.
16. Y. A. Al-Soud, N. A. Al-Masoudi, Il Farmaco 2004, 59, 41-46.
17. A. O. Maslat, M. Abussaud, H. Tashtoush, M. AL-Talib, Pol. J. Pharmacol. 2002, 54, 55-59.
18. M. Daoudi, N. B. Larbi, D. Benjelloun, A. Kerbal, Molecule 2002, 7, 690-696.
19. S. Ahadi, G. Shakibaei, I. Peiman, P. Mirzaei, A. Bazgir, Heterocycles. 2008, 75 (9), 2293-2299.
20. M. N. Purohit, G. V. Pujar, K. V. Manohar, R. H. Udupi, G. S. Vijayakumar, Indian J. Heterocyclic Chem. 2006, 16, 93-94.
21. M. T. Omar, Arch. Pharm. Res. 1997, 20, 602-609.
22. S. N. Manjula, N. M. Noolvi, K. V. Parihar, S. A. M. Reddy, et al., Eur. J. Med. Chem. 2009, 44, 2923-2929.
23. A. Molinari, C. Ojeda, A. Oliva, J. M. Corral, et al., Arch. Pharm. Chem. Life Sci. 2009, 342, 591-599.
24. S. A. F. Rostom, H. M. A. Ashour, H. A. A. El Razik, Arch. Pharm. Chem. Life Sci. 2009, 342, 299-310.
25. K. H. Chandramouli, K. N. Thimmaiah, A. Chandrasekhar, C. J. M. D'Souza, Nucleosides Nucleotides Nucleic Acids 2004, 10, 1639-1656.